ArticleBritish journal of clinical pharmacology2021

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Tobias Litzenburger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.